Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04580485
Title INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation

urinary bladder cancer

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

ovarian cancer

prostate cancer


INCB106385 + Retifanlimab


Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | BEL

No variant requirements are available.